Reshape Lifesciences INC Schedule 13G passive stakes

L1 Capital Global Opportunities Master Fund, Ltd. has filed an amended Schedule 13G, disclosing beneficial ownership of 0.33% of ReShape Lifesciences Inc.'s common stock.

CVI Investments and Heights Capital Management report 0% beneficial ownership in ReShape Lifesciences Inc., indicating a full divestment.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri reported a combined beneficial ownership of 0.003% in ReShape Lifesciences Inc. common stock.

L1 Capital Global Opportunities Master Fund, Ltd. has reported a 9.85% beneficial ownership stake in ReShape Lifesciences Inc., as detailed in a recent Schedule 13G filing with the SEC.

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have jointly disclosed beneficial ownership of 5.71% of ReShape Lifesciences Inc.'s common stock, primarily through warrants.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a beneficial ownership of 5.7% in ReShape Lifesciences Inc., primarily through warrants.

Leonite Fund I, LP and Avi Geller have jointly disclosed a beneficial ownership of 6.05% in ReShape Lifesciences Inc., holding 200,000 common shares.

FirstFire Global Opportunities Fund LLC has reported a 6.05% passive ownership stake in ReShape Lifesciences Inc., holding 200,000 shares of common stock.

Multiple investment entities and Michael Bigger have reported the sale of their entire beneficial ownership in ReShape Lifesciences Inc., reducing their collective stake from nearly 10% to zero as of February 19, 2025.

CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., have jointly disclosed a beneficial ownership of 9.9% of ReShape Lifesciences Inc.'s common stock.